Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Inclusion Criteria: Signed and written informed consent * Male or female patients age ≥ 18 years * Histologically confirmed diagnosis of non-metastatic clear-cell renal cell carcinoma of intermediate to high risk with completely resectable primary tumours. * World Health Organization performance status of 0-1. * Adequate coagulation function as defined in protocol * Adequate hematological function as defined in protocol * Adequate hepatic function as defined in protocol * Adequate renal function as defined in protocol * Negative serum pregnancy test at screening for women of childbearing potential. * Highly effective contraception for both male and female subjects if the risk of conception exists. Exclusion Criteria: Renal tumors of low risk or M1 * Non-clear cell histology at biopsy * Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product * Corrected QT interval (QTc) \> 480 msecs * History of any of the cardiovascular conditions defined in the protocol within the past 6 months * Poorly controlled hypertension * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. * Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer * Evidence of active bleeding or bleeding diathesis. * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. * Unable or unwilling to discontinue use of prohibited medications to be listed in protocol for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study * Treatment with any of the following anti-cancer therapies: chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of axitinib or avelumab * Administration of any non-oncologic investigational drug within 30 days or 5 half lives whichever is longer prior to receiving the first dose of study treatment * Prior organ transplantation, including allogeneic stem cell transplantation * Significant acute or chronic infections as defined in protocol * Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent * Known severe hypersensitivity reactions to monoclonal antibodies * Pregnancy or lactation * Known alcohol or drug abuse